Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms
Philadelphia-negative classical myeloproliferative neoplasms (MPNs) include polycythemia
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …
vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The 2016 …
Epidemiology of the classical myeloproliferative neoplasms: the four corners of an expansive and complex map
RM Shallis, R Wang, A Davidoff, X Ma, NA Podoltsev… - Blood reviews, 2020 - Elsevier
The classical myeloproliferative neoplasms (MPNs), specifically chronic myeloid leukemia
(CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …
(CML), polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis …
Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001–12
SA Srour, SS Devesa, LM Morton… - British journal of …, 2016 - Wiley Online Library
Descriptive epidemiological information on myeloproliferative neoplasms (MPN s) and
myelodysplastic (MDS)/MPN s is largely derived from single institution and European …
myelodysplastic (MDS)/MPN s is largely derived from single institution and European …
Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
AM Vannucchi, T Barbui, F Cervantes… - Annals of …, 2015 - annalsofoncology.org
According to the 2008 World Health Organization (WHO) classification, classical
Philadelphia chromosome/BCR-ABL negative chronic myeloproliferative neoplasms (MPNs) …
Philadelphia chromosome/BCR-ABL negative chronic myeloproliferative neoplasms (MPNs) …
Impact of mutational profile on the management of myeloproliferative neoplasms: a short review of the emerging data
GG Loscocco, P Guglielmelli… - OncoTargets and …, 2020 - Taylor & Francis
Philadelphia-chromosome negative myeloproliferative neoplasms (MPN) are a
heterogeneous group of clonal hematopoietic stem cell disorders characterized by an …
heterogeneous group of clonal hematopoietic stem cell disorders characterized by an …
[HTML][HTML] Myeloid malignancies in the real-world: Occurrence, progression and survival in the UK's population-based Haematological Malignancy Research Network …
Background Population-based information on cancer incidence, prevalence and outcome
are required to inform clinical practice and research; but contemporary data are lacking for …
are required to inform clinical practice and research; but contemporary data are lacking for …
Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients
J Rohmer, A Couteau‐Chardon… - American Journal of …, 2020 - Wiley Online Library
Abstract FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia (F/P+ MN‐eo) is a
rare disease: robust epidemiological data are lacking and reported issues are scarce, of low …
rare disease: robust epidemiological data are lacking and reported issues are scarce, of low …
[HTML][HTML] Proteogenetic drug response profiling elucidates targetable vulnerabilities of myelofibrosis
MHE Wildschut, J Mena, C Dördelmann… - Nature …, 2023 - nature.com
Myelofibrosis is a hematopoietic stem cell disorder belonging to the myeloproliferative
neoplasms. Myelofibrosis patients frequently carry driver mutations in either JAK2 or …
neoplasms. Myelofibrosis patients frequently carry driver mutations in either JAK2 or …
Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States
S Verstovsek, J Yu, RM Scherber, S Verma… - Leukemia & …, 2022 - Taylor & Francis
This analysis examined trends in incidence and survival among US adults with
myeloproliferative neoplasms, including essential thrombocythemia (ET; n= 14,676) …
myeloproliferative neoplasms, including essential thrombocythemia (ET; n= 14,676) …
[HTML][HTML] Safety and efficacy of zinpentraxin alfa as monotherapy or in combination with ruxolitinib in myelofibrosis: stage I of a phase II trial
S Verstovsek, L Foltz, V Gupta, R Hasserjian… - …, 2023 - ncbi.nlm.nih.gov
Abstract Pentraxin 2 (PTX-2; serum amyloid P component), a circulating endogenous
regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients …
regulator of the inflammatory response to tissue injury and fibrosis, is reduced in patients …